535PENCORAFENIB (LGX818), AN ORAL BRAF INHIBITOR, IN PATIENTS (PTS) WITH BRAF V600E METASTATIC COLORECTAL CANCER (MCRC): RESULTS OF DOSE EXPANSION IN AN OPEN-LABEL, PHASE 1 STUDY

C.A. Gomez-Roca1, J. Delord1, C. Robert2, M. Hidalgo3, R. von Moos4, A. Arance5, E. Elez6, D. Michel7, A. Seroutou8, T. Demuth7, J. Tabernero6 Dept. Medical Oncology, Centre Claudius-Regaud, Toulouse, FRANCE Dermatology, Institut Gustave Roussy, Villejuif, FRANCE CIOCC, Centro Integral Oncologico Clara Campal, Madrid, SPAIN Medizinische Onkologie, Kantonspital Graubunden, Chur, SWITZERLAND Medical Oncology, Hospital Clinic, Barcelona, SPAIN Medical Oncology, Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, SPAIN Clinical Trial, Novartis Pharma AG, Basel, SWITZERLAND Statistics, Novartis Pharma AG, Basel, SWITZERLAND